Skip to main content
Canna~Fangled Abstracts

β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms

By September 9, 2021September 28th, 2021No Comments
. 2021 Sep 9;12:722476.

doi: 10.3389/fphar.2021.722476. eCollection 2021.

Xiang-Hu He 1 2, Ewa Galaj 1, Guo-Hua Bi 1, Yi He 1, Briana Hempel 1, Yan-Lin Wang 2, Eliot L Gardner 1, Zheng-Xiong Xi 1
Affiliations 

Abstract

Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction. However, it is unclear whether β-caryophyllene (BCP), a natural product with a CB2 receptor agonist profile, has therapeutic effects on methamphetamine (METH) abuse and dependence. In this study, we used animal models of self-administration, electrical brain-stimulation reward (BSR) and in vivo microdialysis to explore the effects of BCP on METH-taking and METH-seeking behavior. We found that systemic administration of BCP dose-dependently inhibited METH self-administration under both fixed-ratio and progressive-ratio reinforcement schedules in rats, indicating that BCP reduces METH reward, METH intake, and incentive motivation to seek and take METH. The attenuating effects of BCP were partially blocked by AM 630, a selective CB2 receptor antagonist. Genetic deletion of CB2 receptors in CB2-knockout (CB2-KO) mice also blocked low dose BCP-induced reduction in METH self-administration, suggesting possible involvement of a CB2 receptor mechanism. However, at high doses, BCP produced a reduction in METH self-administration in CB2-KO mice in a manner similar as in WT mice, suggesting that non-CB2 receptor mechanisms underlie high dose BCP-produced effects. In addition, BCP dose-dependently attenuated METH-enhanced electrical BSR and inhibited METH-primed and cue-induced reinstatement of drug-seeking in rats. In vivo microdialysis assays indicated that BCP alone did not produce a significant reduction in extracellular dopamine (DA) in the nucleus accumbens (NAc), while BCP pretreatment significantly reduced METH-induced increases in extracellular NAc DA in a dose-dependent manner, suggesting a DA-dependent mechanism involved in BCP action. Together, the present findings suggest that BCP might be a promising therapeutic candidate for the treatment of METH use disorder.

 

Keywords: CB2 receptor, dopamine, methamphetamine, reinstatement, self-administration, β-caryophyllene

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

FIGURE 5

FIGURE 6

References

    1. Al Mansouri S., Ojha S., Al Maamari E., Al Ameri M., Nurulain S. M., Bahi A. (2014). The Cannabinoid Receptor 2 Agonist, β-caryophyllene, Reduced Voluntary Alcohol Intake and Attenuated Ethanol-Induced Place Preference and Sensitivity in Mice. Pharmacol. Biochem. Behav. 124, 260–268. 10.1016/j.pbb.2014.06.025 – DOI – PubMed
    1. Altshuler R. D., Lin H., Li X. (2020). Neural Mechanisms Underlying Incubation of Methamphetamine Craving: A Mini-Review. Pharmacol. Biochem. Behav. 199, 173058. 10.1016/j.pbb.2020.173058 – DOI – PMC – PubMed
    1. Aracil-Fernández A., Trigo J. M., García-Gutiérrez M. S., Ortega-Álvaro A., Ternianov A., Navarro D., et al. (2012). Decreased Cocaine Motor Sensitization and Self-Administration in Mice Overexpressing Cannabinoid CB₂ Receptors. Neuropsychopharmacology 37, 1749–1763. 10.1038/npp.2012.22 – DOI – PMC – PubMed
    1. Atwood B. K., Mackie K. (2010). CB2: a Cannabinoid Receptor with an Identity Crisis. Br. J. Pharmacol. 160, 467–479. 10.1111/j.1476-5381.2010.00729.x – DOI – PMC – PubMed
    1. Bahi A., Al Mansouri S., Al Memari E., Al Ameri M., Nurulain S. M., Ojha S. (2014). β-Caryophyllene, a CB2 Receptor Agonist Produces Multiple Behavioral Changes Relevant to Anxiety and Depression in Mice. Physiol. Behav. 135, 119–124. 10.1016/j.physbeh.2014.06.003 – DOI – PubMed

Leave a Reply